Ignite Creation Date:
2025-12-24 @ 12:57 PM
Ignite Modification Date:
2026-01-06 @ 2:35 AM
Study NCT ID:
NCT04081961
Status:
COMPLETED
Last Update Posted:
2020-03-03
First Post:
2019-09-04
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Feasibility Study to Use Biosensing Devices to Monitor PA and Resp. Function in Smokers w and w/o Resp. Symptoms/COPD
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D012818', 'term': 'Signs and Symptoms, Respiratory'}], 'ancestors': [{'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'baurzhan.zhussupov@gmail.com', 'phone': '87774822171', 'title': 'Baurzhan Zhussupov', 'organization': 'Kazakhstan Academy of Preventive Medicine'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'timeFrame': '90 days after participant was recruited to the study', 'eventGroups': [{'id': 'EG000', 'title': 'Asymptomatic Current Smokers', 'description': 'No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device', 'otherNumAtRisk': 9, 'deathsNumAtRisk': 9, 'otherNumAffected': 0, 'seriousNumAtRisk': 9, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': '"Grey Zone" Current Smokers', 'description': 'Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device', 'otherNumAtRisk': 9, 'deathsNumAtRisk': 9, 'otherNumAffected': 0, 'seriousNumAtRisk': 9, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Current Smokers With COPD', 'description': 'Current smokers with a confirmed diagnosis of COPD (GOLD stage I-III)\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device', 'otherNumAtRisk': 9, 'deathsNumAtRisk': 9, 'otherNumAffected': 0, 'seriousNumAtRisk': 9, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Rate of Recruitment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '29', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}, {'value': '21', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Asymptomatic Current Smokers', 'description': 'No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device'}, {'id': 'OG001', 'title': '"Grey Zone" Current Smokers', 'description': 'Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device'}, {'id': 'OG002', 'title': 'Current Smokers With COPD', 'description': 'Current smokers with a confirmed diagnosis of COPD (GOLD stage I-III)\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device'}], 'classes': [{'categories': [{'measurements': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline', 'description': 'Recruitment is defined as the number of potential participants screened for study eligibility versus the number of persons who enrolled in the study.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The number of potential participants screened for study eligibility'}, {'type': 'PRIMARY', 'title': 'Rate of Retention', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Asymptomatic Current Smokers', 'description': 'No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device'}, {'id': 'OG001', 'title': '"Grey Zone" Current Smokers', 'description': 'Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device'}, {'id': 'OG002', 'title': 'Current Smokers With COPD', 'description': 'Current smokers with a confirmed diagnosis of COPD (GOLD stage I-III)\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device'}], 'classes': [{'categories': [{'measurements': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'through study completion, an average of 90 days', 'description': 'Retention is defined as the proportion of participants enrolled who completed the intervention and all study measures.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'Participants recruited to the study'}, {'type': 'PRIMARY', 'title': 'Protocol Adherence', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'Asymptomatic Current Smokers', 'description': 'No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device'}, {'id': 'OG001', 'title': '"Grey Zone" Current Smokers', 'description': 'Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device'}, {'id': 'OG002', 'title': 'Current Smokers With COPD', 'description': 'Current smokers with a confirmed diagnosis of COPD (GOLD stage I-III)\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device'}], 'classes': [{'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '8', 'groupId': 'OG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'through study completion, an average of 90 days', 'description': 'Adherence to the study protocol is determined as the proportion of participants enrolled from whom all mHealth parameters registered every day.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Asymptomatic Current Smokers', 'description': 'No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device'}, {'id': 'FG001', 'title': '"Grey Zone" Current Smokers', 'description': 'Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device'}, {'id': 'FG002', 'title': 'Current Smokers With COPD', 'description': 'Current smokers with a confirmed diagnosis of COPD (GOLD stage I-III)\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '9'}, {'groupId': 'FG001', 'numSubjects': '9'}, {'groupId': 'FG002', 'numSubjects': '9'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '9'}, {'groupId': 'FG001', 'numSubjects': '9'}, {'groupId': 'FG002', 'numSubjects': '9'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}, {'value': '27', 'groupId': 'BG003'}]}], 'groups': [{'id': 'BG000', 'title': 'Asymptomatic Current Smokers', 'description': 'No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device'}, {'id': 'BG001', 'title': '"Grey Zone" Current Smokers', 'description': 'Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device'}, {'id': 'BG002', 'title': 'Current Smokers With COPD', 'description': 'Current smokers with a confirmed diagnosis of COPD (GOLD stage I-III)\n\nAnamed OEM device; Air Next mobile spirometry device: Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device'}, {'id': 'BG003', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}, {'value': '27', 'groupId': 'BG003'}]}], 'categories': [{'measurements': [{'value': '50.9', 'groupId': 'BG000', 'lowerLimit': '44', 'upperLimit': '58'}, {'value': '50.8', 'groupId': 'BG001', 'lowerLimit': '42', 'upperLimit': '58'}, {'value': '51.4', 'groupId': 'BG002', 'lowerLimit': '44', 'upperLimit': '59'}, {'value': '51.0', 'groupId': 'BG003', 'lowerLimit': '42', 'upperLimit': '59'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'FULL_RANGE'}, {'title': 'Sex: Female, Male', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}, {'value': '27', 'groupId': 'BG003'}]}], 'categories': [{'title': 'Female', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '6', 'groupId': 'BG003'}]}, {'title': 'Male', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '7', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}, {'value': '21', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race and Ethnicity Not Collected', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'populationDescription': 'Race and Ethnicity were not collected from any participant.'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'Kazakhstan', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}, {'value': '27', 'groupId': 'BG003'}]}], 'categories': [{'measurements': [{'value': '9', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}, {'value': '27', 'groupId': 'BG003'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2019-06-03', 'size': 2037018, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2019-12-18T08:20', 'hasProtocol': True}, {'date': '2019-07-14', 'size': 573511, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2019-12-18T08:21', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 27}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2019-06-07', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-02', 'completionDateStruct': {'date': '2019-10-31', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-02-18', 'studyFirstSubmitDate': '2019-09-04', 'resultsFirstSubmitDate': '2019-12-18', 'studyFirstSubmitQcDate': '2019-09-06', 'lastUpdatePostDateStruct': {'date': '2020-03-03', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2019-12-18', 'studyFirstPostDateStruct': {'date': '2019-09-09', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2020-01-09', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-10-10', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Rate of Recruitment', 'timeFrame': 'Baseline', 'description': 'Recruitment is defined as the number of potential participants screened for study eligibility versus the number of persons who enrolled in the study.'}, {'measure': 'Rate of Retention', 'timeFrame': 'through study completion, an average of 90 days', 'description': 'Retention is defined as the proportion of participants enrolled who completed the intervention and all study measures.'}, {'measure': 'Protocol Adherence', 'timeFrame': 'through study completion, an average of 90 days', 'description': 'Adherence to the study protocol is determined as the proportion of participants enrolled from whom all mHealth parameters registered every day.'}]}, 'conditionsModule': {'conditions': ['Signs and Symptoms, Respiratory', 'Mobile Applications', 'Activity Trackers', 'Respiratory Function Tests']}, 'referencesModule': {'references': [{'pmid': '32213479', 'type': 'DERIVED', 'citation': 'Sharman A, Zhussupov B, Sharman D, Kim I. Evaluating Mobile Apps and Biosensing Devices to Monitor Physical Activity and Respiratory Function in Smokers With and Without Respiratory Symptoms or Chronic Obstructive Pulmonary Disease: Protocol for a Proof-of-Concept, Open-Label, Feasibility Study. JMIR Res Protoc. 2020 Mar 26;9(3):e16461. doi: 10.2196/16461.'}]}, 'descriptionModule': {'briefSummary': 'This study examines the feasibility and acceptability of using mobile applications and biosensing (mHealth) devices in detecting vitality parameters in current smokers with and without respiratory symptoms/COPD (e.g., heart rate, blood oxygenation, steps/motion) for a future big-scale study.', 'detailedDescription': 'The study is designed to investigate feasibility of using mHealth devices to improve the treatment, assessment, compliance, and outcomes in smokers with and without respiratory symptoms/COPD. The study aims to reveal and address the anticipated barriers to the acceptance and implementation of mHealth devices in this patient population and clinical setting. As is well documented, the more attention patients receive from medical personnel, the better their clinical outcomes. Here we are attempting to use device-driven monitoring applications, interactive reminders, and teaching modules to deliver a constant positive feedback loop to patients to improve their health decisions.\n\nObjectives of the study:\n\nTo assess the feasibility of using mHealth devices in current smokers with and without respiratory symptoms/COPD.\n\nTo assess the utility (i.e., validity and reproducibility) of mHealth devices in detecting vitality parameters in current smokers with and without respiratory symptoms/COPD (e.g., heart rate; blood oxygenation; steps/motion; FEV1, FVC, and their ratio; peak expiratory flow \\[PEF\\]).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '59 Years', 'minimumAge': '40 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Residents of City of Almaty aged 40-59 who smoke conventional cigarettes with a minimum of 10 pack-year smoking history', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Current smokers who are currently smoking conventional cigarettes with a minimum of 10 pack-year smoking history\n* Able to use and willing to be trained to use mHealth devices\n\nExclusion Criteria:\n\n* COPD exacerbation that has not resolved at least 28 days prior to screening\n* COPD exacerbation occurring after screening but before the first study visit\n* Pneumonia or other respiratory tract infections that have not resolved at least 14 days prior to screening\n* Pneumonia occurring after screening but before the first study visit\n* Active respiratory disorders: tuberculosis, lung cancer, significant bronchiectasis, sarcoidosis, bronchial asthma, lung fibrosis, pulmonary hypertension, interstitial lung diseases, or other active pulmonary diseases\n* Any co-morbid medical condition that in the opinion of the investigator would make participation in the study unsafe or unfeasible, including conditions that prohibit completion of exercise testing\n* Use of supplemental oxygen therapy\n* Inability to abstain from smoking during the period in which the participant is admitted to the Kazakhstan Academy of Preventive Medicine (KAPM) COPD Center\n* A history of allergy or hypersensitivity to metal, particularly stainless steel\n* Any vital sign indicator, for example, hypertension or tachycardia at rest that, at the discretion of the investigator, would make participation in the study unsafe or unfeasible\n* Women who test positive for pregnancy during screening, lactating women, or women planning on becoming pregnant during the study\n* Participants using assistive devices like walking aids, as these are likely to interfere with physical activity'}, 'identificationModule': {'nctId': 'NCT04081961', 'briefTitle': 'Feasibility Study to Use Biosensing Devices to Monitor PA and Resp. Function in Smokers w and w/o Resp. Symptoms/COPD', 'organization': {'class': 'OTHER', 'fullName': 'Kazakhstan Academy of Preventive Medicine'}, 'officialTitle': 'A Proof-of-concept, Open-label, Feasibility Study to Evaluate Mobile Applications and Biosensing (mHealth) Devices to Monitor Physical Activity and Respiratory Function in Smokers With and Without Respiratory Symptoms/COPD', 'orgStudyIdInfo': {'id': 'PMI.IIS.2016.1.'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Asymptomatic current smokers', 'description': 'No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)', 'interventionNames': ['Device: Anamed OEM device; Air Next mobile spirometry device']}, {'label': '"Grey zone" current smokers', 'description': 'Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.', 'interventionNames': ['Device: Anamed OEM device; Air Next mobile spirometry device']}, {'label': 'Current smokers with COPD', 'description': 'Current smokers with a confirmed diagnosis of COPD (GOLD stage I-III)', 'interventionNames': ['Device: Anamed OEM device; Air Next mobile spirometry device']}], 'interventions': [{'name': 'Anamed OEM device; Air Next mobile spirometry device', 'type': 'DEVICE', 'description': 'Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device', 'armGroupLabels': ['"Grey zone" current smokers', 'Asymptomatic current smokers', 'Current smokers with COPD']}]}, 'contactsLocationsModule': {'locations': [{'zip': '050008', 'city': 'Almaty', 'country': 'Kazakhstan', 'facility': 'Kazakhstan Academy of Preventive Medicine', 'geoPoint': {'lat': 43.25249, 'lon': 76.9115}}], 'overallOfficials': [{'name': 'Almaz Sharman, Dr', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Kazakhstan Academy of Preventive Medicine'}]}, 'ipdSharingStatementModule': {'url': 'http://www.intervals.science', 'infoTypes': ['STUDY_PROTOCOL'], 'timeFrame': 'Data will be available after May 1, 2020 without time limit.', 'ipdSharing': 'YES', 'description': "The dataset after the re-identification will be available to other researchers on the 'www.intervals.science' platform."}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Kazakhstan Academy of Preventive Medicine', 'class': 'OTHER'}, 'collaborators': [{'name': 'Philip Morris International', 'class': 'INDUSTRY'}, {'name': 'Synergy Research Group', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}